RxDoctor Payments Data

Maria Correa, MD

Internal Medicine · San Juan, PRNPI 1215907381

Payments from drug & device makers

$3,256in general payments, 2019–2025

Across 30 payments — averaging $108.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Immunogen, Inc.$1K
  • Boehringer Ingelheim$723
  • AstraZeneca$494
  • Johnson & Johnson$428
  • Merck$100
  • E.r. Squibb & Sons, L.L.C.$100
  • plus $157 from 6 others

What the payments were for

  • Speaking & faculty fees$1,18236%
  • Food & beverage$2,05963%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,256 in reported general payments places this provider in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,346
Medicare patients
21
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$27,948
EliquisApixaban36$26,364
SynthroidLevothyroxine Sodium234$24,702
XareltoRivaroxaban22$22,455
FarxigaDapagliflozin Propanediol25$21,488
JanuviaSitagliptin Phosphate13$20,820
Janumet XrSitagliptin Phos/Metformin Hcl14$18,061
LantusInsulin Glargine,hum.Rec.Anlog79$8,398
Metoprolol Succinate296$6,691
Atorvastatin Calcium510$6,051
Diclofenac Potassium151$4,369
Fenofibrate111$4,037
Losartan Potassium254$3,930
Irbesartan89$3,617
Tolterodine Tartrate ErTolterodine Tartrate35$3,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$100$38,88227 claims
Boehringer IngelheimJardiance$723$27,94832 claims
AbbVieSynthroid$45$24,702234 claims
Johnson & JohnsonXarelto$428$22,45522 claims
AstraZenecaFarxiga$494$21,48825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →